Traditional Chinese medicine composition for treating muscae volitantes

Abstract

The invention relates to a traditional Chinese medicine composition for treating muscae volitantes. The traditional Chinese medicine composition is prepared from 5-20 parts by weight of prepared rehmannia root, 3-18 parts by weight of angelica sinensis, 3-18 parts by weight of rhizoma nelumbinis charcoal, 3-18 parts by weight of hairyvein agrimony, 3-18 parts by weight of barbary wolfberry fruit, 3-18 parts by weight of chrysanthemum, 3-18 parts by weight of wine-steamed dogwood, 3-18 parts by weight of plantain seed, 3-18 parts by weight of vinegar-processed tortoise shell, 3-18 parts by weight of fried immature bitter orange, 1-10 parts by weight of white paeony root, 1-10 parts by weight of uncaria and 1-8 parts by weight of ligusticum wallichii. The traditional Chinese medicine composition for treating the muscae volitantes is remarkable in curative effect, safe, reliable, few in adverse reaction, simple in preparation process operation and suitable for industrial production.

Description

Technical Field

[0001] The present invention relates to the field of traditional Chinese medicine, and in particular to a traditional Chinese medicine composition for treating floaters. Background Art

[0002] As we age, changes in the composition of the vitreous body lead to vitreous liquefaction and collapse, which can form and precipitate, eventually forming symptomatic vitreous opacities, commonly known as floaters. Floaters are a subjective feeling of discomfort, which is the visual perception of dots, lines, rings or blocks formed by the projection of vitreous opacities on the retina. Vitreous opacities can cause light scattering in the eye and decreased contrast sensitivity, affecting visual quality and the normal work and life of patients. Some patients cannot tolerate the distress caused by vitreous opacities and may experience symptoms of anxiety and depression. Posterior vitreous detachment progresses significantly with age, especially between the ages of 40 and 70 or above. Posterior vitreous detachment progresses significantly faster in female eyes than in male eyes.

[0003] Current Western medical treatments for floaters include iodine preparations and surgical procedures (such as laser ablation and vitrectomy). The iodine contained in aminoiodine peptide eye drops can stimulate metabolic processes within the eye, promoting the absorption and resolution of turbidity. Furthermore, the medication can improve ocular blood circulation and alleviate discomfort caused by vitreous opacities. However, iodine treatment should be avoided in patients with hyperthyroidism, iodine allergy, or chronic thyroid disease.

[0004] Laser ablation, which involves vaporizing the vitreous fluid within the vitreous cavity while ensuring adequate light penetration, involves cutting a vitreous strip within the optic axis. The efficacy rate for treating floaters ranges from 50% to 77%. However, these reports primarily focus on Weiss ring-shaped floaters, which are the most effective type for laser treatment. Laser treatment of floaters can cause posterior lens capsule damage, retinal hemorrhage, retinal tears, and retinal detachment. Laser ablation can also lead to blockage of the trabecular meshwork by fragmented vitreous opacities, macrophages, and inflammatory cells, and damage to the trabecular meshwork endothelium during laser treatment, resulting in open-angle glaucoma. Currently, the available evidence to guide clinical practice is very limited and conflicting. Vitrectomy, a surgical procedure that involves complete or partial removal of the vitreous, can effectively remove vitreous opacities. However, vitrectomy is an invasive intraocular procedure and carries the risks of endophthalmitis, iatrogenic tears, retinal detachment, and cataract formation.

[0005] Floaters, described in Traditional Chinese Medicine as "clouds and mist moving in the eyes," are closely related to the liver, kidneys, and gallbladder. Traditional Chinese Medicine considers floaters a syndrome of underlying deficiency and superficial excess, with liver and kidney deficiency, Qi and blood deficiency, and internal accumulation of phlegm and dampness as the primary pathogenesis. Treatments are indicated to tonify the kidneys and liver, invigorate Qi and resolve phlegm, and promote blood circulation and improve eyesight.

[0006] Currently, there are few reports on effective traditional Chinese medicines for the treatment of floaters. Therefore, there is still an urgent need to develop a traditional Chinese medicine that can effectively improve the fundus lesions and blood rheology levels of patients with vitreous opacities, improve patients' vision and the clinical treatment efficacy of floaters. Summary of the Invention

[0007] To solve the above technical problems, the present invention includes the following aspects:

[0008] A first aspect of the present invention provides a traditional Chinese medicine composition for treating floaters, which is prepared from Rehmannia root, Chinese angelica root, lotus root charcoal, agrimony, wolfberry, chrysanthemum, wine-steamed cornus officinalis, plantain seed, vinegar-cooked tortoise shell, stir-fried immature bitter orange, white peony root, Uncaria rhynchophylla and Chuanxiong.

[0009] Preferably, the traditional Chinese medicine composition is made of 5-20 weight parts of Rehmannia root, 3-18 weight parts of Angelica sinensis, 3-18 weight parts of lotus node charcoal, 3-18 weight parts of Agrimoniae scabra, 3-18 weight parts of Lycium barbarum, 3-18 weight parts of Chrysanthemum, 3-18 weight parts of wine-steamed Cornus officinalis, 3-18 weight parts of Plantago seed, 3-18 weight parts of vinegar-cooked tortoise shell, 3-18 weight parts of stir-fried Citrus aurantium, 1-10 weight parts of White Peony Root, 1-10 weight parts of Uncaria rhynchophylla and 1-8 weight parts of Ligusticum chuanxiong.

[0010] More preferably, the traditional Chinese medicine composition is made from 8-18 parts by weight of Rehmannia root, 5-15 parts by weight of Angelica sinensis, 5-15 parts by weight of lotus node charcoal, 5-15 parts by weight of Agrimoniae scabra, 5-15 parts by weight of Lycium barbarum, 5-15 parts by weight of Chrysanthemum, 5-15 parts by weight of wine-steamed Cornus officinalis, 5-15 parts by weight of Plantago seed, 5-15 parts by weight of Vinegar-cooked Tortoise Shell, 5-15 parts by weight of stir-fried Citrus aurantium, 2-10 parts by weight of White Peony Root, 2-10 parts by weight of Uncaria rhynchophylla and 1-5 parts by weight of Ligusticum chuanxiong.

[0011] Further preferably, the traditional Chinese medicine composition is made from 10-15 parts by weight of Rehmannia root, 8-12 parts by weight of Angelica sinensis, 8-12 parts by weight of lotus node charcoal, 8-12 parts by weight of Agrimoniae scabra, 8-12 parts by weight of Lycium barbarum, 8-12 parts by weight of Chrysanthemum, 8-12 parts by weight of Cornus officinalis steamed with wine, 8-12 parts by weight of Plantago seed, 8-12 parts by weight of tortoise shell with vinegar, 8-12 parts by weight of stir-fried Citrus aurantium, 4-8 parts by weight of White Peony Root, 4-8 parts by weight of Uncaria rhynchophylla and 2-4 parts by weight of Ligusticum chuanxiong.

[0012] Most preferably, the traditional Chinese medicine composition is made of 12 parts by weight of Rehmannia root, 10 parts by weight of Angelica sinensis, 10 parts by weight of lotus node charcoal, 10 parts by weight of Agrimoniae scabra, 10 parts by weight of Lycium barbarum, 10 parts by weight of Chrysanthemum, 10 parts by weight of Cornus officinalis steamed with wine, 10 parts by weight of Plantago seed, 10 parts by weight of tortoise shell with vinegar, 10 parts by weight of stir-fried Citrus aurantium, 6 parts by weight of White Peony Root, 6 parts by weight of Uncaria rhynchophylla and 3 parts by weight of Ligusticum chuanxiong.

[0013] Preferably, the traditional Chinese medicine composition further comprises pharmaceutically acceptable excipients.

[0014] Preferably, the Chinese medicine composition is an oral preparation.

[0015] Preferably, the dosage form of the Chinese medicine composition is tablets, capsules, granules, tincture or decoction.

[0016] More preferably, the dosage form of the Chinese medicine composition is granules.

[0017] Preferably, the preparation method of the traditional Chinese medicine composition comprises the following steps: weighing the prescribed amount of Rehmannia root, Angelica sinensis, lotus root charcoal, Agrimoniae scabra, Lycium barbarum, Chrysanthemum, wine-steamed Cornus officinalis, Plantago seed, vinegar-soaked tortoise shell, stir-fried Citrus aurantium, White Peony Root, Uncaria rhynchophylla and Ligusticum chuanxiong, mixing and crushing, adding purified water 4-8 times the total weight of the medicinal materials, boiling and then decocting on low heat for 30-60 minutes, filtering and concentrating the traditional Chinese medicine filtrate to 1-2 times the total weight of the traditional Chinese medicine initially added, drying and dry granulating the powder, crushing and sieving to obtain the product.

[0018] Preferably, purified water in an amount 6 times the total weight of the medicinal materials is added in the preparation method.

[0019] Preferably, in the preparation method, the mixture is boiled and then simmered on low heat for 60 minutes.

[0020] Preferably, in the preparation method, the traditional Chinese medicine filtrate is concentrated to twice the total weight of the initially added traditional Chinese medicine.

[0021] The second aspect of the present invention provides a method for preparing the above-mentioned traditional Chinese medicine composition, which comprises the following steps: weighing a prescribed amount of Rehmannia root, Angelica sinensis, lotus root charcoal, Agrimoniae scabra, Lycium barbarum, Chrysanthemum, wine-steamed Cornus officinalis, Plantago seed, vinegar-soaked tortoise shell, stir-fried Citrus aurantium, White Peony Root, Uncaria rhynchophylla and Ligusticum chuanxiong, mixing and crushing, adding purified water 4-8 times the total weight of the medicinal materials, boiling and then decocting on low heat for 30-60 minutes, filtering and concentrating the traditional Chinese medicine filtrate to 1-2 times the total weight of the traditional Chinese medicine initially added, drying and dry-granulating the powder, crushing and sieving to obtain the product.

[0022] Preferably, purified water in an amount 6 times the total weight of the medicinal materials is added in the preparation method.

[0023] Preferably, in the preparation method, the mixture is boiled and then simmered over low heat for 60 minutes.

[0024] Preferably, in the preparation method, the traditional Chinese medicine filtrate is concentrated to twice the total weight of the initially added traditional Chinese medicine.

[0025] The third aspect of the present invention provides use of the above-mentioned traditional Chinese medicine composition in the preparation of a medicament for treating floaters.

[0026] Preferably, the floaters include physiological floaters or pathological floaters.

[0027] Preferably, the floaters are caused by proliferative vitreoretinopathy.

[0028] A fourth aspect of the present invention provides use of the above-mentioned traditional Chinese medicine composition in the preparation of a medicament for treating proliferative vitreoretinopathy.

[0029] The prepared rehmannia root in the Chinese medicine composition of the present invention greatly nourishes the liver and kidneys and nourishes the yin of blood; the white peony root nourishes the blood, restrains the yin and harmonizes the circulation; the angelica root nourishes the blood and activates the blood circulation; the ligusticum chuanxiong activates the blood circulation and removes stagnation; the wolfberry fruit nourishes the liver and kidney yin, benefits the essence, and improves the eyesight; the Uncaria rhynchophylla and the chrysanthemum clear the liver and calm the liver yang; the steamed cornus officinalis with wine nourishes the kidney qi and benefits the kidney essence; the tortoise shell with vinegar nourishes the kidney and liver yin and suppresses the yang; the lotus root node charcoal and the agrimony herb astringe and stop bleeding; the stir-fried bitter orange invigorates the qi and the plantain seed promotes diuresis, prevents the tonics from being greasy, effectively improves the patient's blood and qi circulation, and achieves the requirement of improving eyesight.

[0030] The technical effects produced by the present invention are:

[0031] Based on extensive screening experiments and optimized traditional Chinese medicine components and proportions, the present invention has developed an oral traditional Chinese medicine granule formulation with significant efficacy in treating floaters. The traditional Chinese medicine composition of the present invention is effective, safe, reliable, has minimal adverse reactions, and features a simple preparation process, making it suitable for industrial production. DETAILED DESCRIPTION

[0032] Example 1

[0033] Weigh 12 g of Rehmannia root, 10 g of Angelica sinensis, 10 g of lotus node charcoal, 10 g of Agrimoniae, 10 g of Lycium barbarum, 10 g of chrysanthemum, 10 g of wine-steamed Cornus officinalis, 10 g of Plantago seed, 10 g of tortoise shell with vinegar, 10 g of stir-fried Citrus aurantium, 6 g of White Peony Root, 6 g of Uncaria rhynchophylla, and 3 g of Ligusticum chuanxiong, mix and grind the mixture, add 700 mL of purified water, boil, then simmer on low heat for 60 minutes, filter, and concentrate the traditional Chinese medicine filtrate to 200 mL. After drying, dry-granulate the powder, grind, and sieve to obtain the traditional Chinese medicine granule 1 of the present invention.

[0034] Example 2

[0035] Weigh 12 g of Rehmannia root, 15 g of Angelica sinensis, 15 g of lotus node charcoal, 5 g of Herba Agrimoniae, 5 g of Lycium barbarum, 10 g of chrysanthemum, 10 g of wine-steamed Cornus officinalis, 10 g of Plantago seed, 10 g of Vinegar-sweetened Carapace of Tortoise Shell, 10 g of stir-fried Citrus aurantium, 6 g of White Peony Root, 6 g of Uncaria rhynchophylla, and 3 g of Ligusticum chuanxiong, mix and grind the mixture, add 700 mL of purified water, boil, then simmer on low heat for 60 minutes, filter, and concentrate the traditional Chinese medicine filtrate to 200 mL. After drying, dry-granulate the powder, grind, and sieve to obtain the traditional Chinese medicine granules 2 of the present invention.

[0036] Example 3

[0037] Weigh 12 g of Rehmannia root, 10 g of Angelica sinensis, 10 g of lotus node charcoal, 10 g of Agrimoniae herb, 10 g of Lycium barbarum, 15 g of chrysanthemum, 15 g of wine-steamed Cornus officinalis, 5 g of Plantago seed, 5 g of Vinegar-soaked Tortoise shell, 10 g of stir-fried Citrus aurantium, 6 g of White Peony root, 6 g of Uncaria rhynchophylla, and 3 g of Ligusticum chuanxiong, mix and grind the mixture, add 700 mL of purified water, boil, then simmer on low heat for 60 minutes, filter, and concentrate the traditional Chinese medicine filtrate to 200 mL. After drying, dry-granulate the powder, grind, and sieve to obtain the traditional Chinese medicine granules 3 of the present invention.

[0038] Test Example 1: Efficacy of the Chinese medicine composition of the present invention on proliferative vitreoretinopathy

[0039] 1. Test method

[0040] 60 adult Belgian pigmented rabbits weighing 2.5-3kg, of either sex, were selected and randomly divided into 4 groups, namely the control group and Example 1-3 groups, with 15 rabbits in each group. The experimental animals were fasted from food and water for 24 hours before surgery. Before surgery, compound tropicamide eye drops were applied to both eyes to fully dilate the pupils. 2% sodium pentobarbital was slowly injected into the ear vein for general anesthesia at a dose of 1ml / kg. At the same time, proparacaine hydrochloride eye drops were applied to the operated eye for surface anesthesia. The eyes were flushed with povidone iodine, especially the conjunctival sac. The eyelids were opened with an eyelid speculum, and the nasal corneal margin was fixed with microtweezers. A needle was inserted vertically into the sclera 4mm behind the corneal margin above the temporal region to extract 0.2ml of vitreous humor. A 1ml insulin syringe was used to inject the pre-prepared intraocular injection solution (ARPE-19 cells cultured in vitro were prepared into 2×10 5 Cells / 0.1ml DMEM / F12 cell suspension, 2.5μl 20μg / ml PDGF-BB (50ng) was added to each cell suspension and evenly beaten to obtain an intraocular injection solution), and the sclera was perpendicular to the 4mm place above the temporal corneal margin and injected into the vitreous cavity to construct a proliferative vitreoretinopathy (PVR) animal model. On the 3rd day after surgery, the animals in the Example 1-3 groups were orally administered with the granules prepared in the Example 1-3 of the present invention at a dosage of 5mL of liquid medicine / kg body weight (the granules were diluted with purified water to form a solution of 0.1g / mL), and the control group was orally administered with normal saline of the same dose, once a day, for 26 consecutive days. Each test group animal was observed and recorded the changes in wound, cornea, anterior chamber and vitreous retina on the 28th day after surgery, and graded and assessed with reference to the following Fastenberg rating standard.

[0041] Grading Fundus changes Level 0 Vitreous opacity with cell clusters, no pathological changes Level 1 Vitreous membrane formation without traction Level 2 Localized retinal traction, blood vessels are too high and twisted Level 3 Localized retinotomyel detachment Level 4 Extensive retinal detachment, complete detachment of the medullary cord Level 5 Complete retinal detachment, retinal tears and folds

[0042] 2. Test results

[0043] On the 28th day after modeling, the fundus of the animals in each experimental group was examined and graded according to the Fastenberg grading standard. The specific results are shown in Table 1 below.

[0044] Table 1 PVR grading of the fundus of animals in each experimental group on the 28th day (n=2)

[0045] grade control group Example 1 group Example 2 group Example 3 group Level 0 0 0 0 0 Level 1 0 6 4 3 Level 2 1 8 7 6 Level 3 4 1 4 5 Level 4 4 0 0 1 Level 5 6 0 0 0

[0046] As shown in Table 1 above, compared to the control group, the Fastenberg grade of the experimental animals treated with the Chinese herbal granules of Examples 1-3 of the present invention was significantly reduced overall, indicating that the Chinese herbal composition of the present invention can significantly inhibit the development of experimental PVR in rabbits. It is expected that the Chinese herbal composition of the present invention will be clinically effective in treating proliferative vitreoretinopathy and the associated floaters. Surprisingly, given the same total weight of the Chinese herbal medicines, the treatment effect of Group 1 for PVR was superior to that of Groups 2 and 3, yielding an unexpectedly excellent therapeutic effect.

[0047] Test Example 2: Observation on the clinical efficacy of the Chinese medicine of the present invention combined with aminoiodine peptide eye drops in the treatment of floaters

[0048] 1. Test method

[0049] 1.1 General Information

[0050] This study included 72 patients (72 eyes, with only patients complaining of floaters in one eye) who visited the Ophthalmology Center of Yinzhou People's Hospital, Ningbo University, between January and December 2024. Twenty-three patients (23 eyes) were male and 49 patients (49 eyes) were female. Their ages ranged from 50 to 76 years, with an average of 59.42 ± 6.43 years. The duration of onset ranged from 1 to 90 days, with an average of 20.88 ± 21.34 days.

[0051] The patients were randomly divided into an observation group and a control group according to their odd-even visit numbers. In the observation group, there were 11 males (11 eyes) and 25 females (25 eyes) with an average age of (58.53±5.89) years. In the control group, there were 12 males (12 eyes) and 24 females (24 eyes) with an average age of (60.31±6.89) years. There were no statistically significant differences in age and gender between the two groups (P>0.05).

[0052] 1.2 Inclusion and Exclusion Criteria

[0053] A retrospective cohort study was conducted. Diagnostic criteria for floaters: Patients complain of dark shadows floating before their eyes that move with eye movement; slit lamp examination with a 90D lens reveals vitreous opacities such as dust, streaks, webs, and floccules that move with eye movement.

[0054] Inclusion criteria: 1. Patients diagnosed with vitreous opacities through relevant examinations; 2. Age ≥50 years old; and those who have not taken relevant treatment drugs in the past month.

[0055] Exclusion criteria included breastfeeding or pregnant women; patients with vitreous opacities caused by other retinal diseases (diabetic retinopathy, retinal vein occlusion, hypertensive retinopathy, retinal tears); patients with ocular inflammation or congenital visual impairment; patients with vitreous hemorrhage; patients with glaucoma; patients with high myopia; patients with a history of intraocular surgery such as cataracts; and patients with iodine allergy or thyroid disease. This study was approved by the hospital's medical ethics committee.

[0056] 1.3 Test methods

[0057] Patients were randomly divided into groups according to the odd and even number of visits. The control group was treated with aminoiodine peptide eye drops in the affected eye 3-4 times a day for 2 months. The observation group was orally treated with the granules prepared in Example 1 of the present invention (1 dose per day, twice a day in the morning and afternoon, dissolved in water), and aminoiodine peptide eye drops were administered to the affected eye 3-4 times a day for 2 months.

[0058] 1.4 Detection Method

[0059] (1) Use the international standard visual acuity chart to examine the visual acuity of all participants before treatment and 2 months after treatment;

[0060] (2) The two groups of eyes were examined by B-ultrasound before treatment and 2 months after treatment, and the degree of vitreous opacity was scored (0-3 points), with 0 point being no obvious opacity and 1-3 points being mild, moderate, and severe opacity;

[0061] (3) Two groups of UWF (Ultra wide Angle fundus imaging) were examined before treatment and 2 months after treatment. The projection of the vitreous opacity in the first eye position in front of the retina was observed, the boundary of the opacity was outlined, and the area of ​​the opacity was measured using the built-in software.

[0062] (4) Post-treatment questionnaire on satisfaction with improvement of floater symptoms, with a score of 0-10, where 0 is unsatisfied and 10 is very satisfied. The score is based on the individual's subjective feelings and recorded in the medical record.

[0063] 1.5 Statistical Analysis

[0064] SPSS 22.0 software was used for statistical analysis. Statistical description was performed. Paired t-test was used for comparison within the group, and independent sample t-test was used for comparison between groups. If P < 0.05, the difference was considered statistically significant.

[0065] 2. Test results

[0066] 2.1. Onset time and intraocular pressure

[0067] The average onset time of the observation group was (20.03±21.41) days, and the average intraocular pressure was (15.11±3.05) mmHg. The average onset time of the control group was (21.72±21.55) days, and the average intraocular pressure was (15.21±3.06) mmHg. There was no statistically significant difference in onset time and intraocular pressure between the two groups (P>0.05).

[0068] 2.2 Best corrected visual acuity

[0069] There was no statistically significant difference in the best corrected visual acuity between the observation group and the control group before treatment (P>0.05). After 2 months of treatment, the best corrected visual acuity of both groups improved, and the differences in changes compared with the pre-treatment levels within the same group were statistically significant (P<0.01). However, the visual acuity of the observation group improved better than that of the control group (P<0.05).

[0070] 2.3. Vitreous opacity score

[0071] There was no statistically significant difference in B-ultrasound vitreous opacity scores between the observation group and the control group before treatment (P>0.05). After treatment, there were statistically significant differences in the B-ultrasound vitreous opacity scores of the two groups compared with those before treatment (P<0.01). However, the B-ultrasound vitreous opacity score of the observation group decreased and was better than that of the control group (P<0.05).

[0072] 2.4 UWF Vitreous Opacity Imaging Area

[0073] There was no statistically significant difference in the UWF vitreous opacity imaging area between the observation group and the control group before treatment (P>0.05). Two months after treatment, the changes in the UWF vitreous opacity imaging area in both groups were statistically significant (P<0.01). However, the UWF vitreous opacity imaging area in the observation group decreased, and the change was better than that in the control group (P<0.05).

[0074] Table 2 Comparison of visual acuity, vitreous opacity scores and UWF vitreous opacity area between the two experimental groups (x±s)

[0075]

[0076] Note: Before and after treatment, the same group * P<0.01; comparison between groups after treatment, # P<0.05

[0077] 2.5 Comparison of treatment satisfaction evaluation

[0078] The treatment satisfaction evaluation of the observation group and the control group was compared. The average satisfaction score of the observation group was (8.14±0.99) points, which was significantly better than the average score of the control group (7.75±0.50 points). The difference was statistically significant (P<0.05).

[0079] In summary, the use of the Chinese medicine composition of the present invention in combination with aminoiodine peptide eye drops to treat patients with floaters showed that the visual acuity of the observation group after treatment was significantly higher than that of the control group, and the patients' treatment satisfaction was better than that of the control group. Objectively, the B-ultrasound score of the patients' vitreous opacity was significantly better than that of the control group, and the reduction in the turbid area that could be visualized by UWF was significantly greater than that of the control group, indicating that the Chinese medicine composition of the present invention combined with aminoiodine peptide eye drops has a more significant effect than the single use of aminoiodine peptide eye drops in the treatment of floaters. In addition, the above-mentioned combination regimen can synergistically improve hemodynamics, and no patients experienced ocular or systemic adverse reactions during the entire treatment process. It has high safety and is worthy of clinical promotion and application.

[0080] Although specific embodiments of the present invention have been described, it will be appreciated by those skilled in the art that various changes and modifications may be made to the present invention without departing from the scope or spirit of the present invention. Therefore, the present invention is intended to cover all such changes and modifications that fall within the scope of the appended claims and their equivalents.

Claims

1. A Chinese medicine composition for treating floaters, characterized in that: The traditional Chinese medicine composition is prepared from prepared rehmannia root, angelica root, lotus root node charcoal, agrimony, wolfberry fruit, chrysanthemum, wine-steamed cornus officinalis, plantain seed, vinegar-cooked tortoise shell, stir-fried immature bitter orange, white peony root, Uncaria rhynchophylla and Chuanxiong rhizome.

2. The Chinese medicine composition according to claim 1, characterized in that The traditional Chinese medicine composition is prepared from 5-20 parts by weight of Rehmannia root, 3-18 parts by weight of Chinese angelica, 3-18 parts by weight of lotus root node charcoal, 3-18 parts by weight of Agrimoniae, 3-18 parts by weight of wolfberry, 3-18 parts by weight of chrysanthemum, 3-18 parts by weight of wine-steamed Cornus officinalis, 3-18 parts by weight of Plantago seed, 3-18 parts by weight of tortoise shell prepared with vinegar, 3-18 parts by weight of stir-fried Citrus aurantium, 1-10 parts by weight of white peony root, 1-10 parts by weight of Uncaria rhynchophylla and 1-8 parts by weight of Ligusticum chuanxiong.

3. The Chinese medicine composition according to claim 2, characterized in that The traditional Chinese medicine composition is prepared from 8-18 parts by weight of Rehmannia root, 5-15 parts by weight of Chinese angelica, 5-15 parts by weight of lotus root node charcoal, 5-15 parts by weight of Agrimoniae, 5-15 parts by weight of wolfberry, 5-15 parts by weight of chrysanthemum, 5-15 parts by weight of wine-steamed Cornus officinalis, 5-15 parts by weight of Plantago seed, 5-15 parts by weight of tortoise shell prepared with vinegar, 5-15 parts by weight of stir-fried Citrus aurantium, 2-10 parts by weight of white peony root, 2-10 parts by weight of Uncaria rhynchophylla and 1-5 parts by weight of Ligusticum chuanxiong.

4. The Chinese medicine composition according to claim 3, characterized in that The traditional Chinese medicine composition is prepared from 10-15 parts by weight of Rehmannia root, 8-12 parts by weight of Chinese angelica, 8-12 parts by weight of lotus root node charcoal, 8-12 parts by weight of Agrimoniae, 8-12 parts by weight of wolfberry, 8-12 parts by weight of chrysanthemum, 8-12 parts by weight of wine-steamed Cornus officinalis, 8-12 parts by weight of Plantago seed, 8-12 parts by weight of tortoise shell prepared with vinegar, 8-12 parts by weight of stir-fried Citrus aurantium, 4-8 parts by weight of white peony root, 4-8 parts by weight of Uncaria rhynchophylla, and 2-4 parts by weight of Ligusticum chuanxiong.

5. The Chinese medicine composition according to claim 4, characterized in that The traditional Chinese medicine composition is prepared from 12 parts by weight of Rehmannia root, 10 parts by weight of Chinese angelica, 10 parts by weight of lotus node charcoal, 10 parts by weight of Agrimoniae, 10 parts by weight of wolfberry, 10 parts by weight of chrysanthemum, 10 parts by weight of wine-steamed Cornus officinalis, 10 parts by weight of Plantago seed, 10 parts by weight of tortoise shell with vinegar, 10 parts by weight of stir-fried Citrus aurantium immaturus, 6 parts by weight of white peony root, 6 parts by weight of Uncaria rhynchophylla and 3 parts by weight of Ligusticum chuanxiong.

6. The Chinese medicine composition according to any one of claims 1 to 5, characterized in that The traditional Chinese medicine composition further includes pharmaceutically acceptable excipients.

7. The Chinese medicine composition according to claim 6, characterized in that The Chinese medicine composition is an oral preparation.

8. The Chinese medicine composition according to claim 7, characterized in that The dosage form of the Chinese medicine composition is tablets, capsules, granules, tinctures or decoctions.

9. The method for preparing the Chinese medicine composition according to any one of claims 1 to 8, characterized in that: The method comprises the following steps: weighing a prescribed amount of prepared rehmannia root, angelica root, lotus root charcoal, agrimony, wolfberry fruit, chrysanthemum, wine-steamed cornus officinalis, plantain seed, vinegar-cooked tortoise shell, stir-fried immature bitter orange, white peony root, Uncaria rhynchophylla and ligusticum chuanxiong, mixing and crushing the mixture, adding purified water 4-8 times the total weight of the medicinal materials, boiling the mixture and then decocting it on low heat for 30-60 minutes, filtering and concentrating the Chinese medicinal filtrate to 1-2 times the total weight of the Chinese medicinal materials initially added, drying the mixture, dry-granulating the medicinal powder, crushing the powder and sieving the powder to obtain the medicinal product.

10. Use of the traditional Chinese medicine composition according to any one of claims 1 to 8 in the preparation of a medicament for treating floaters.

Images